vs
徕博科（LH）与美盛公司（MOS）财务数据对比。点击上方公司名可切换其他公司
徕博科的季度营收约是美盛公司的1.2倍（$3.5B vs $3.0B），徕博科净利率更高（4.7% vs -17.5%，领先22.2%），美盛公司同比增速更快（5.6% vs 5.6%），徕博科自由现金流更多（$490.3M vs $-405.7M），过去两年美盛公司的营收复合增速更高（5.3% vs 5.2%）
徕博科（Labcorp）是全球领先的生命科学与诊断检测企业，面向医疗机构、制药企业和个人患者提供全面的临床检验服务、药物研发支持及医疗检测解决方案，依托先进科研经验与创新技术输出准确可落地的健康洞察，助力临床决策、加快新药研发，提升全球患者健康水平。
美盛公司（The Mosaic Company）是总部位于美国佛罗里达州坦帕的化工企业，主营磷矿、钾矿开采及尿素采集，依托多元国际分销网络和旗下肥料业务板块生产销售农用肥料，是美国规模最大的钾肥、磷肥生产商。
LH vs MOS — 直观对比
营收规模更大
LH
是对方的1.2倍
$3.0B
营收增速更快
MOS
高出0.0%
5.6%
净利率更高
LH
高出22.2%
-17.5%
自由现金流更多
LH
多$896.0M
$-405.7M
两年增速更快
MOS
近两年复合增速
5.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $3.5B | $3.0B |
| 净利润 | $164.7M | $-519.5M |
| 毛利率 | 28.2% | 11.5% |
| 营业利润率 | 7.6% | -3.4% |
| 净利率 | 4.7% | -17.5% |
| 营收同比 | 5.6% | 5.6% |
| 净利润同比 | 14.9% | -407.4% |
| 每股收益（稀释后） | $1.98 | $-1.63 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LHMOS
| Q4 25 | $3.5B | $3.0B | ||
| Q3 25 | $3.6B | $3.5B | ||
| Q2 25 | $3.5B | $3.0B | ||
| Q1 25 | $3.3B | $2.6B | ||
| Q4 24 | $3.3B | $2.8B | ||
| Q3 24 | $3.3B | $2.8B | ||
| Q2 24 | $3.2B | $2.8B | ||
| Q1 24 | $3.2B | $2.7B |
净利润LHMOS
| Q4 25 | $164.7M | $-519.5M | ||
| Q3 25 | $261.1M | $411.4M | ||
| Q2 25 | $237.9M | $410.7M | ||
| Q1 25 | $212.8M | $238.1M | ||
| Q4 24 | $143.4M | $169.0M | ||
| Q3 24 | $169.3M | $122.2M | ||
| Q2 24 | $205.3M | $-161.5M | ||
| Q1 24 | $228.0M | $45.2M |
毛利率LHMOS
| Q4 25 | 28.2% | 11.5% | ||
| Q3 25 | 28.8% | 16.0% | ||
| Q2 25 | 29.7% | 17.3% | ||
| Q1 25 | 28.3% | 18.6% | ||
| Q4 24 | 26.9% | 10.7% | ||
| Q3 24 | 27.6% | 14.8% | ||
| Q2 24 | 28.8% | 14.0% | ||
| Q1 24 | 28.2% | 14.9% |
营业利润率LHMOS
| Q4 25 | 7.6% | -3.4% | ||
| Q3 25 | 11.1% | 9.8% | ||
| Q2 25 | 11.2% | 8.1% | ||
| Q1 25 | 9.7% | 12.9% | ||
| Q4 24 | 6.5% | 3.5% | ||
| Q3 24 | 7.7% | 4.1% | ||
| Q2 24 | 9.2% | 8.3% | ||
| Q1 24 | 10.1% | 6.5% |
净利率LHMOS
| Q4 25 | 4.7% | -17.5% | ||
| Q3 25 | 7.3% | 11.9% | ||
| Q2 25 | 6.7% | 13.7% | ||
| Q1 25 | 6.4% | 9.1% | ||
| Q4 24 | 4.3% | 6.0% | ||
| Q3 24 | 5.2% | 4.3% | ||
| Q2 24 | 6.4% | -5.7% | ||
| Q1 24 | 7.2% | 1.7% |
每股收益（稀释后）LHMOS
| Q4 25 | $1.98 | $-1.63 | ||
| Q3 25 | $3.12 | $1.29 | ||
| Q2 25 | $2.84 | $1.29 | ||
| Q1 25 | $2.52 | $0.75 | ||
| Q4 24 | $1.72 | $0.53 | ||
| Q3 24 | $2.00 | $0.38 | ||
| Q2 24 | $2.43 | $-0.50 | ||
| Q1 24 | $2.69 | $0.14 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $532.3M | $276.6M |
| 总债务越低越好 | — | $4.3B |
| 股东权益账面价值 | $8.6B | $12.1B |
| 总资产 | $18.4B | $24.5B |
| 负债/权益比越低杠杆越低 | — | 0.35× |
8季度趋势，按日历期对齐
现金及短期投资LHMOS
| Q4 25 | $532.3M | $276.6M | ||
| Q3 25 | $598.1M | $153.3M | ||
| Q2 25 | $647.3M | $286.2M | ||
| Q1 25 | $369.4M | $259.2M | ||
| Q4 24 | $1.5B | $272.8M | ||
| Q3 24 | $1.5B | $301.6M | ||
| Q2 24 | $265.1M | $322.0M | ||
| Q1 24 | $99.3M | $336.7M |
总债务LHMOS
| Q4 25 | — | $4.3B | ||
| Q3 25 | — | $3.4B | ||
| Q2 25 | — | $3.3B | ||
| Q1 25 | — | $3.3B | ||
| Q4 24 | — | $3.3B | ||
| Q3 24 | — | $3.2B | ||
| Q2 24 | — | $3.2B | ||
| Q1 24 | — | $3.2B |
股东权益LHMOS
| Q4 25 | $8.6B | $12.1B | ||
| Q3 25 | $8.7B | $12.8B | ||
| Q2 25 | $8.5B | $12.4B | ||
| Q1 25 | $8.3B | $11.8B | ||
| Q4 24 | $8.1B | $11.5B | ||
| Q3 24 | $8.2B | $11.8B | ||
| Q2 24 | $8.0B | $11.7B | ||
| Q1 24 | $8.0B | $12.0B |
总资产LHMOS
| Q4 25 | $18.4B | $24.5B | ||
| Q3 25 | $18.3B | $24.7B | ||
| Q2 25 | $18.1B | $24.3B | ||
| Q1 25 | $17.6B | $23.2B | ||
| Q4 24 | $18.4B | $22.9B | ||
| Q3 24 | $18.6B | $23.3B | ||
| Q2 24 | $16.7B | $22.6B | ||
| Q1 24 | $16.5B | $22.9B |
负债/权益比LHMOS
| Q4 25 | — | 0.35× | ||
| Q3 25 | — | 0.26× | ||
| Q2 25 | — | 0.27× | ||
| Q1 25 | — | 0.28× | ||
| Q4 24 | — | 0.29× | ||
| Q3 24 | — | 0.27× | ||
| Q2 24 | — | 0.27× | ||
| Q1 24 | — | 0.27× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $614.2M | $-56.1M |
| 自由现金流经营现金流 - 资本支出 | $490.3M | $-405.7M |
| 自由现金流率自由现金流/营收 | 13.9% | -13.6% |
| 资本支出强度资本支出/营收 | 3.5% | 11.8% |
| 现金转化率经营现金流/净利润 | 3.73× | — |
| 过去12个月自由现金流最近4个季度 | $1.2B | $-534.6M |
8季度趋势，按日历期对齐
经营现金流LHMOS
| Q4 25 | $614.2M | $-56.1M | ||
| Q3 25 | $387.2M | $228.5M | ||
| Q2 25 | $620.6M | $609.5M | ||
| Q1 25 | $18.5M | $42.9M | ||
| Q4 24 | $777.2M | $219.3M | ||
| Q3 24 | $277.3M | $312.9M | ||
| Q2 24 | $561.1M | $847.0M | ||
| Q1 24 | $-29.8M | $-80.0M |
自由现金流LHMOS
| Q4 25 | $490.3M | $-405.7M | ||
| Q3 25 | $280.5M | $-135.9M | ||
| Q2 25 | $542.7M | $304.9M | ||
| Q1 25 | $-107.5M | $-297.9M | ||
| Q4 24 | $665.1M | $-74.8M | ||
| Q3 24 | $161.5M | $72.1M | ||
| Q2 24 | $432.9M | $513.1M | ||
| Q1 24 | $-163.6M | $-463.0M |
自由现金流率LHMOS
| Q4 25 | 13.9% | -13.6% | ||
| Q3 25 | 7.9% | -3.9% | ||
| Q2 25 | 15.4% | 10.1% | ||
| Q1 25 | -3.2% | -11.4% | ||
| Q4 24 | 20.0% | -2.7% | ||
| Q3 24 | 4.9% | 2.6% | ||
| Q2 24 | 13.4% | 18.2% | ||
| Q1 24 | -5.2% | -17.3% |
资本支出强度LHMOS
| Q4 25 | 3.5% | 11.8% | ||
| Q3 25 | 3.0% | 10.6% | ||
| Q2 25 | 2.2% | 10.1% | ||
| Q1 25 | 3.8% | 13.0% | ||
| Q4 24 | 3.4% | 10.4% | ||
| Q3 24 | 3.5% | 8.6% | ||
| Q2 24 | 4.0% | 11.9% | ||
| Q1 24 | 4.2% | 14.3% |
现金转化率LHMOS
| Q4 25 | 3.73× | — | ||
| Q3 25 | 1.48× | 0.56× | ||
| Q2 25 | 2.61× | 1.48× | ||
| Q1 25 | 0.09× | 0.18× | ||
| Q4 24 | 5.42× | 1.30× | ||
| Q3 24 | 1.64× | 2.56× | ||
| Q2 24 | 2.73× | — | ||
| Q1 24 | -0.13× | -1.77× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LH
| Diagnostics | $2.7B | 78% |
| Biopharma Laboratory Services | $793.0M | 23% |
MOS
暂无分部数据
